22nd October 2016
CVT-301 is the name of an inhaled version of L-dopa presently being developed for the
treatment of Parkinson's Disease. CVT-301 uses the ARCUS inhalation technology, which
delivers a reliable and consistent drug dose with a compact, breath actuated inhaler. It uses a
dry powder and inhaler combination that is unique in its ability to deliver a large, precise
dose independent of inspiratory flow rate from a simple, easy-to-use device suitable for
convenient self-administration.
Among people with Parkinson's Disease inhaling CVT-301
as a single 50mg dose during an "off" period, 77% of them
showed an increase in plasma L-dopa within 10 minutes.
Only 27% of those people with Parkinson's Disease taking
oral carbidopa/levodopa reached the same levels. The
improvements in motor function were seen as quickly as 5
and 15 minutes after administration, which were the earliest
assessment times. So the effect may have been even quicker.
The most common adverse event was a cough. However, all cough events were mild to
moderate, occurred at the time of inhalation, resolved rapidly, and became less frequent after
initial dosing. Less common adverse effects were dizziness and headache. There were no
adverse effects on cardiovascular or lung function.
The speed of effect of the L-dopa inhaler and its limited adverse effects could enable it to be
widely used when a rapid effect on Parkinson's Disease is required.
Reference : Science Translational Medicine [2016] 8 (360) : 360ra136 (M.M.Lipp, R.
Batycky, J.Moore, M.Leinonen, M.I.Freed)
Complete abstract : http://www.ncbi.nlm.nih.gov/pubmed/27733560
http://www.viartis.net/parkinsons.disease/news/161022.pdf
mail@viartis.net
©2016 Viartis
http://www.viartis.net/parkinsons.disease/news/161022.pdf
No comments:
Post a Comment